Ridgetech Inc (Nasdaq:RDGT), a wholesale distributor of pharmaceutical and other healthcare products in China, announced on Monday its financial results for the fiscal year ended 31 March 2025.
Revenue totalled USD119.97m, down from USD123.99m in the same period of last year.
Gross profit was USD3.84m, compared to USD4.88m a year earlier, while gross margin was 3.2% compared to 3.9% in the year to 31 March 2024.
Ridgetech reported net income of USD10.20m, or USD1.84 per basic and diluted earnings per share, compared to a net loss of USD4.23m, or USD2.93 per basic and diluted loss per share, for the same period a year ago.
As of 31 March 2025 the company had cash and cash equivalents of USD12.78m, an increase from USD2.30m as of 31 March 2024.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government